WO2004031155A1 - ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF - Google Patents
ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF Download PDFInfo
- Publication number
- WO2004031155A1 WO2004031155A1 PCT/EP2003/011034 EP0311034W WO2004031155A1 WO 2004031155 A1 WO2004031155 A1 WO 2004031155A1 EP 0311034 W EP0311034 W EP 0311034W WO 2004031155 A1 WO2004031155 A1 WO 2004031155A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carboxamide
- azepine
- dihydro
- hydroxy
- dibenz
- Prior art date
Links
- 0 CC=CC(N(C(N)=O)c1c(C2)cccc1)=C(CC#*)[C@@]2O Chemical compound CC=CC(N(C(N)=O)c1c(C2)cccc1)=C(CC#*)[C@@]2O 0.000 description 1
- BMPDWHIDQYTSHX-AWEZNQCLSA-N NC(N(c1c(C2)cccc1)c1ccccc1[C@H]2O)=O Chemical compound NC(N(c1c(C2)cccc1)c1ccccc1[C@H]2O)=O BMPDWHIDQYTSHX-AWEZNQCLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
Definitions
- the invention relates to a novel process for the manufacture of substituted enantiopure 10- hydroxy-dihydrodibenz[b,f]azepines by transfer hydrogenation of 10-oxo-dihydro- dibenz[b,f]azepines, to novel catalysts and new crystal forms of both enantiomers of 10,11- dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide, obtainable by the new process.
- Substituted dihydrodibenz[b,f]azepines are understood to be those active agents which may be preferably used to prevent and treat some central and peripheric nervous system disorders. These compounds are well known and some of them have been used widely for the treatment of some pathological states in humans. For example, 5H-dibenz[b,f]azepine-5- carboxamide (carbamazepine) has become established as an effective agent in the management of epilepsy. An analogue of carbamazepine, 10,11 -dihydro-10-oxo-5H- dibenzo[b,f]azepine-5-carbamide (oxcarbazepine, see e.g.
- German Patent 2.011.087) exhibits comparable antiepileptical activity with less side effects than carbamazepine.
- Oxcarbazepine is metabolized in mammals to 10,11 -dihydro-10-hydroxy-5H- dibenz[b,f]azepine-5-carboxamide (see e.g. Belgian Patent 747.086).
- the objective of the present invention is to provide an enantioselective synthesis of substituted 10-hydroxy-dihydrodibenzo[b,f]azepines resulting in high yields and moreover guaranteeing a minimization of the ecological pollution of the environment, being economically attractive, e.g. by using less steps in the reaction and/or process sequence for the manufacture of 10,11 -dihydro-10-hydroxy-5H-dibenzo[b,f]azepine-5-carboxamide, and leading to largely enantiomerically pure target products and to products that are possible to crystallize.
- another objective of the present invention is to provide a process that can be carried out in a larger scale and can thus be used as production process.
- the present invention provides a process for the production of a compound of formula la or lb
- each of R 1 and R 2 are hydrogen, halogen, amino or nitro; and each of R 3 and R 4 , independently, are hydrogen or C Cealkyl; which process comprises the step of reducing a compound of formula II
- R 1 , R 2 , R 3 and R 4 are as defined above; in the presence of a hydrogen donor and a reducing agent selected from the group consisting of a compound of formula (Ilia), (1Mb), (IVa), (IVb), (Va), (Vb), (Via) or (Vlb)
- M is Ru, Rh, Ir, Fe, Co or Ni
- L-i is hydrogen
- L. 2 represents an aryl or aryl-aliphatic residue
- Hal is halogen
- R 5 is an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, aryl or aryl-aliphatic residue, which, in each case, may be linked to a polymer; each of R 6 and R 7 , independently, is an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, aryl or aryl-aliphatic residue; each of R 8 and R 9 is phenyl or R 8 and R 9 form together with the carbon atom to which they are attached a cyclohexane or cyclopentane ring; and
- R 17 is H, halogen, amino, nitro or C r C 6 alkoxy.
- Any aromatic residue of a compound of formula (Ilia), (1Mb), (IVa), (IVb), (Va), (Vb), (Via) or (Vlb) is substituted or, preferably, unsubstituted. If it is substituted, it may be substituted, for example, by one or more, e.g. two or three, residues e.g. those selected from the group consisting of C ⁇ -C 7 alkyl, hydroxy, -O-CH 2 -O-, CHO, C 1 -C 7 alkoxy, C 2 -C 8 alkanoyl-oxy, halogen, e.g. Cl or F, nitro, cyano, and CF 3 .
- residues e.g. those selected from the group consisting of C ⁇ -C 7 alkyl, hydroxy, -O-CH 2 -O-, CHO, C 1 -C 7 alkoxy, C 2 -C 8 alkanoyl-oxy, halogen, e
- An aliphatic hydrocarbon residue is, for example, C-*-C 7 alkyl, C 2 -C 7 alkenyl or secondarily C 2 - C 7 alkynyl.
- C 2 -C Alkenyl is in particular C 3 -C 7 alkenyl and is, for example, 2-propenyl or 1-, 2- or 3-butenyl.
- C 3 -C 5 alkenyl is preferred.
- C 2 -C 7 -Alkynyl is in particular C 3 -C 7 alkynyl and is preferably propargyl.
- a cycloaliphatic residue is, for example, a C 3 -C 8 cycloalkyl or, secondarily, C 3 -C 8 cycloalkenyl.
- C 3 -C 8 Cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Cyclopentyl and cyclohexyl are preferred.
- Cycloalkenyl is in particular C 3 -C 7 cycloalkenyl and is preferably cyclopent-2-en-yl and cyclopent-3- enyl, or cyclohex-2-en-yl and cyclohex-3-en-yl.
- a cycloaliphatic-aliphatic residue is, for example, C 3 -C 8 cycloalkyl-CrC 7 alkyl, preferably C 3 - C 6 -cycloalkyl-C ⁇ -C 4 alkyl. Preferred is cyclopropylmethyl.
- An aryl residue is, for example, a carbocyclic or heterocyclic aromatic residue, in particular phenyl or in particular an appropriate 5- or 6-membered and mono or multicyclic residue which has up to four identical or different hetero atoms, such as nitrogen, oxygen or sulfur atoms, preferably one, two, three or four nitrogen atoms, an oxygen atom or a sulfur atom.
- Appropriate 5-membered heteroaryl residues are, for example, monoaza-, diaza-, triaza-, tetraaza-, monooxa- or monothia-cyclic aryl radicals, such as pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl and thienyl, while suitable appropriate 6-membered residues are in particular pyridyl.
- Appropriate multicyclic residues are anthracenyl, phenanthryl, benzo[1 ,3]- dioxole or pyrenyl.
- An aryl residue may be mono-substituted by e.g. NH 2 , OH, SO 3 H, CHO, or di-substituted by OH or CHO and SO 3 H.
- An aryl-aliphatic residue is in particular phenyl-C**-C 7 alkyl, also phenyl-C 2 -C 7 alkenyl or phenyl-C 2 -C 7 alkynyl.
- Halogen represents fluorine, chlorine, bromine or iodine.
- Polymers may be polystyrene (PS), cross-linked PS (J), polyethylene glycol (PEG) or a silica gel residue (Si). Examples are NH-R 15 wherein R 15 is C(O)(CH 2 ) ⁇ -PS or C(O)NH(CH 2 ) n -PS; and -O-Si(R 18 ) 2 (CH 2 )nR 16 wherein n is 1 to 7, R 18 is C r C 6 alkyl, e.g. ethyl, and R 16 is a PS, J, PEG or Si (obtainable by Aldrich, Switzerland).
- M is Ru, Rh, Ir, preferably Ru.
- L 2 is isopropylmethylbenzene, benzene, hexamethylbenzene, mesitylene, preferred is isopropylmethylbenzene.
- R 5 is 2- or 3- or 4-pyridyl, 4-chloro-4-phenoxy-phenyl, 4-phenoxy-phenyl, 5-di(m)ethylamino-
- R 6 and R 7 are phenyl, 4-methylphenyl or 3,5-dimethylphenyl, preferred is phenyl.
- R 8 and R 9 is phenyl or cyclohexyl or substituted phenyl, preferably is phenyl.
- Preferred R 17 is H.
- a preferred hydrogen donor is, for example, a system comprising 2-propanol, 3-pentanol, or most preferably HOOCH in the presence of an amine, such as triethylamine, DBU or other tertiary amines.
- the hydrogen donor may also be used as inert solvent, especially 2- propanol and most preferably HCOOH.
- An alternative hydrogen donor is 2-propanol in the presence of various catalysts and base, e.g.
- the preferred bases are: f-BuOK, KOH or APrOK.
- the invention provides a process for the production of a compound of formula I'a or I'b
- a reducing agent selected from the group consisting of a compound of formula (Ilia), (1Mb), (IVa), (IVb), (Va), (Vb), (Via) or (Vlb) as described above and a hydrogen donor.
- the invention further provides the novel compounds of formula II Pa and lll'b
- n O, 1, 2, 3, 4, 5, 6 or 7;
- X is O or S
- R 10 is polystyrol
- R 11 is silica gel
- R 12 is cross-linked polystyrol
- R 13 is polyethylene-glycol
- R 14 is C C 6 alkyl; and m is 1 , 2 or 3.
- the hydrogenation described above may be carried out, for example in the absence or, customarily, in the presence of a suitable solvent or diluent or a mixture thereof, the reaction, as required, being carried out with cooling, at room temperature or with warming, for example in a temperature range from about - 80°C up to the boiling point of the reaction medium, preferably from about -10° to about +200°C, and, if necessary, in a closed vessel, under pressure, in an inert gas atmosphere and/or under anhydrous conditions.
- the hydrogenation may be carried out in a suitable inert solvent, such as an ether, e.g. tetrahydrofuran, an ester, such as ethylacetate, a halogenated solvent, such as methylen- chloride, supercritical CO 2 , ionic liquids, a nitrile, especially acetonitrile, an amide, such as dimethylformamide or dimethylacetamide and in a temperature range from, for example, from -78°C, to the boiling point of the solvent, preferably at room temperature, e.g. as described in the Examples.
- a suitable inert solvent such as an ether, e.g. tetrahydrofuran, an ester, such as ethylacetate, a halogenated solvent, such as methylen- chloride, supercritical CO 2 , ionic liquids, a nitrile, especially acetonitrile, an amide, such as dimethylformamide or dimethylacetamide
- the compounds of formula (I) may be converted into their corresponding pro-drug esters of formula (VIII)
- Y is unbranched or branched C r C ⁇ 8 alkylcarbonyl, aminoC ⁇ -C 18 alkylcarbonyl, C 3 - Cscycloalkylcarbonyl, C 3 -C 8 cycloalkylC ⁇ -C ⁇ 8 alkylcarbonyl, halogenC r C 18 alkylcarbonyl, unsubstituted or at the aryl substituted C 5 -Ci 0 arylCi-C 18 alkylcarbonyl, unsubstituted or at the heteroaryl substituted C 5 -C ⁇ 0 heteroarylC ⁇ -C ⁇ 8 alkylcarbonyl, C C 18 alkoxycarbonyl; and and R 1 , R 2 , R 3 and R 4 are as described above (see also EP-B1-751129 for production conditions).
- a further objective of the present invention is to provide new crystal forms of both enantiomers of 10,11 -dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide, obtainable by the new process described above, their usage in the production of pharmaceutical preparations, new pharmaceutical preparations comprising these new crystal forms and/or the use of these new crystal forms in the treatment of disorders such as epilepsy, or in the production of pharmaceutical formulations which are suitable for this treatment.
- the present invention also furnishes new crystal forms of both enantiomers of 10,11- dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide, especially to crystal forms described hereinafter as modification A and modification B.
- Modification A can be distinguished from modification B, for instance, by X-ray powder diffraction techniques, IR spectroscopy and melting points.
- the crystal forms can be distinguished in particular by their X-ray powder diffraction pattern.
- X- ray powder diffraction pattern were taken with a diffractometer and using Cu-Ko ⁇ -radiation are preferably used to characterise solids of organic compounds.
- X- ray powder diffraction pattern are used particularly successfully to determine the crystal modification of a substance.
- Table 1 Crystal modification A of (R)- or (S)-10.11-dihvdro-10-hvdroxy-5H- dibenzrb,flazepine-5-carboxamide
- the present invention provides
- crystal modification B of (S)-10,11 -dihydro-10-hydroxy-5H- dibenz[b,f]azepine-5-carboxamide has a melting point between 193.0 and 197.0 °C, especially a melting point between 194.0 and 196.0 °C, e.g. 195.5 °C.
- the present invention also relates to a crystal modification of (S)-10,11 -dihydro-10-hydroxy-5H- dibenz[b,f]azepine-5-carboxamide having a melting point between 193.0 and 197.0 °C especially a melting point between 194.0 and 196.0 °C, e.g. 195.5 °C.
- the invention also relates to a new anhydrous crystal form of (R)- or (S)-10,11 -dihydro-10- hydroxy-5H-dibenz[b,f]azepine-5-carboxamide, which is characterised by a melting enthalpy of between 122 J/g and 136 J/g, preferably between 126 and 131 J/g, more preferably between 128 and 129 J/g.
- Crystal modification A of (R)- or (S)-10,11 -dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5- carboxamide can be obtained by quickly precipitating (R)- or (S)-10,11 -dihydro-10-hydroxy- 5H-dibenz[b,f]azepine-5-carboxamide, respectively, from its solution in a suitable solvent, e.g. dichloromethane, acetone or an alcohol such as ethanol or isopropanol, e.g.
- a suitable solvent e.g. dichloromethane, acetone or an alcohol such as ethanol or isopropanol, e.g.
- Crystal modification B of (R)- or (S)-10,11 -dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5- carboxamide can be obtained from the corresponding crystal modification A or from amorphous material by phase equilibration in a suitable solvent, e.g. by vibration for 12 to 200 hours, e.g. 24 hours, in acetone or ethanol at room temperature.
- a suitable solvent e.g. by vibration for 12 to 200 hours, e.g. 24 hours, in acetone or ethanol at room temperature.
- the time necessary to obtain pure form B depends on the enantiomer and the particular solvent used.
- (S)-10,11 -dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide having crystal modification A can be transferred into (S)-10,11 -dihydro-10-hydroxy-5H-dibenz[b,f]azepine- 5-carboxamide having crystal modification B in acetone at room temperature in less than 24 hours.
- crystal modification B of (R)- or (S)-10,11 -dihydro-10-hydroxy-5H- dibenz[b,f]azepine-5-carboxamide can be obtained by crystallization of (R)- or (S)-10,11- dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide from its solution in a suitable solvent, e.g. an alcohol such as ethanol or isopropanol, especially by adding a crystal of (R)- or (S)-10,11 -dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide, respectively, having crystal modification B.
- a suitable solvent e.g. an alcohol such as ethanol or isopropanol
- the distinct crystal modifications A and B of the (R)- and (S)-enantiomer, respectively, can be obtained in pure form, i.e. the pure entaniomers are obtained in a crystal form which contains less than 10 % of the other crystal form, preferably less than 5 % of the other crystal form, more preferably less than 1 % of the other crystal form.
- the new crystal forms are especially stable, in particular crystal form B is to be regarded as the one which is the thermodynamically stable crystalline form, and they are therefore suitable as active ingredients for solid forms of administration, for storing in solid form or as intermediates (with particularly good storability) in the preparation of solid or liquid forms of administration. Upon storage of modification B, no crystals of modification A should be obtained. Such stable forms are preferred for the preparation of medicaments.
- modification A is better soluble in organic and aqueous solutions than modification B and, hence, is more suitable for the preparation of infusions. Furthermore, modification A can be incorporated in solid dosage forms such as tablets in order to have an improved, in particular a faster, bioavailability than modification B.
- the invention also relates to the use of the new crystal forms in the production of pharmaceutical preparations, new pharmaceutical preparations which contain these new crystal forms, and/or their use in the treatment of epilepsy.
- pharmaceutical preparations or compositions which comprise or contain the active ingredient are mentioned, in the case of liquid compositions or compositions which no longer contain the crystal form as such, this is always understood to mean also the pharmaceutical preparations obtainable using the crystal forms (for example infusion solutions obtained using crystal forms A or B as defined herein), even if they no longer contain the respective crystal form (for example because they exist in solution).
- the invention also relates especially to the use of a new crystal form of (R)- or (S)-10,11- dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide having crystal form A or, preferably, B, in the production of pharmaceutical preparations, characterised by mixing a new crystal form of (R)- or (S)-10,11 -dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5- carboxamide having crystal form A or B with one or more carriers.
- the invention also relates to a method of treating warm-blooded animals suffering from a disorder such as epilepsy, characterised by administering a dose of (R)- or (S)-10,11- dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide which is effective for treating said disease in one of the new crystal forms to a warm-blooded animal requiring such treatment, also including in particular the treatment with those preparations that are produced using one of the new crystal forms; and/or the use of a new crystal form of (R)- or (S)-10,11-dihydro- 10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide having crystal form A or B in such a treatment.
- a disorder such as epilepsy
- the active ingredient may be used for example in such a way that the pharmaceutical preparations contain an effective amount of the active ingredient together or in a mixture with a significant amount of one or more organic or inorganic, liquid or solid, pharmaceutically acceptable carriers.
- compositions according to the invention are those intended for enteral, especially nasal, rectal or oral, or parenteral administration to warm-blooded animals, especially humans, and they contain an effective dose of the active ingredient on its own or together with a significant amount of a pharmaceutically acceptable carrier.
- the dose of the active ingredient is dependent on the type of warm-blooded animal, the body weight, the age and the individual condition, individual pharmacokinetic situations, the disease to be treated and the type of administration.
- DSC investigations are made on a Perkin Elmer DSC 7 instrument or on Perkin Elmer Pyris DSC. About 2-4 mg of drug substance are place into a gold sample pan which is sealed under nitrogen to prevent oxidation during the heating phase. A heating rate of 10°C/min is applied from 25°C to 210°C.
- PXRD is performed on a Philips 1710 powder X-ray diffractometer using Cu K ⁇ radiation.
- the X-ray tube is operated at a Voltage of 40kV, and a current of 40 mA.
- a step size of 0.02°, and a counting time of 2.4 s per step is applied.
- IR is performed on a Perkin-Elmer BX II FT-IR spectrometer. About 1 mg of drug substance are pressed into a KBr pellet. 12 scans at a resolution of 2 cm '1 are acquired. For characterization of the polymorphs ATR-IR is performed using a Greasby Specac Golden Gate Diamond ATR Accessory, Serial No. 2585. About 10 mg of test substance are pressed in the ATR cell using 70cNm.
- Example 1 Procedure for the enantioselective Transfer Hydrogenation of 10-Oxo-10.11- dihvdro-dibenzof/ /lazepine-5-carboxylic acid amide to f?(-)-10.11-Dihvdro-10-hvdroxy-5H- dibenzf/ ⁇ tlazepine-5-carboxamide
- Example 2 Procedure for the enantioselective Transfer Hydrogenation of 10-Oxo-10.11- dihvdro-dibenzori /lazepine-5-carboxylic acid amide to S(+)-10.11-Dihvdro-10-hvdroxy-5H- dibenzf. /lazepine-5-carboxamide
- reaction mixture is cooled to RT, diluted with CH 2 CI 2 (20 ml) and neutralised with aqu. NaHCO 3 . After washing with brine the solution is concentrated under reduced pressure. The residue is purified by flash chromatography on silica gel using a 6:1 EtOAc-MeOH mixture as eluent to afford of S(+)-10,11-Dihydro-10-hydroxy-5H-dibenzo[jb, ]azepine-5-carboxamide.
- Example 4 Crystal modification B of (R)-10.11-Dihvdro-10-hvdroxy-5H-dibenzfb.f1azepine-5- carboxamide 120 mg of crystal modification A of (R)-10,11 -dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5- carboxamide are suspended in 1.0 ml of acetone and the obtained suspension is stirred with a magnetic stirrer shaken for 160 hours at 21 to 25 °C. The product is filtered and dried in air at room temperature providing crystal modification B of (R)-10,11 -dihydro-10-hydroxy-5H- dibenz[b,f]azepine-5-carboxamide in the form of white crystals.
- Example 5 Crystal modification B of (S)-10.11-Dihvdro-10-hvdroxy-5H-dibenzrb.f1azepine-5- carboxamide
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/530,617 US20060142566A1 (en) | 2002-10-07 | 2003-10-06 | Enantioselective process for the preparation of both enantiomers of 10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide and new crystal forms thereof |
EP03798930A EP1551808A1 (en) | 2002-10-07 | 2003-10-06 | ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ b,f AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF |
AU2003276055A AU2003276055B2 (en) | 2002-10-07 | 2003-10-06 | Enantioselective process for the preparation of both enantiomers of 10,11-dihydro-10-hydroxy-5H-dibenz [b,f]azepine-5-carboxamide and new crystal forms thereof |
MXPA05003737A MXPA05003737A (en) | 2002-10-07 | 2003-10-06 | ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF. |
JP2004540788A JP2006504710A (en) | 2002-10-07 | 2003-10-06 | Process for the enantioselective preparation of both enantiomers of 10,11-dihydro-10-hydroxy-5H-dibenz [b, f] azepine-5-carboxamide and its novel crystalline form |
BR0315113-1A BR0315113A (en) | 2002-10-07 | 2003-10-06 | Enantioselective process for the preparation of both 10,11-dihydro-10-hydroxy-5h-dibenz [b, f] azepine-5-carboxamide enantiomers and their crystal forms |
CA002501237A CA2501237A1 (en) | 2002-10-07 | 2003-10-06 | Enantioselective process for the preparation of both enantiomers of 10,11-dihydro-10-hydroxy-5h-dibenz [b,f]azepine-5-carboxamide and new crystal forms thereof |
NO20052244A NO20052244L (en) | 2002-10-07 | 2005-05-06 | Enantioselective process for preparing both enantiomers of 10,11-dihydro-10-hydroxy-5H-dibenzo [b, f] -azepine-5-carboxamide and novel crystal forms thereof |
HK05112208.8A HK1079790A1 (en) | 2002-10-07 | 2005-12-30 | Enantioselective process for the preparation of both enantiomers of 10, 11-dihydro-10-hydroxy-5h-dibenz b,f azepine-5-carboxamide and new crystal forms thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0223224.7A GB0223224D0 (en) | 2002-10-07 | 2002-10-07 | Organic compounds |
GB0223224.7 | 2002-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004031155A1 true WO2004031155A1 (en) | 2004-04-15 |
Family
ID=9945425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/011034 WO2004031155A1 (en) | 2002-10-07 | 2003-10-06 | ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF |
Country Status (20)
Country | Link |
---|---|
US (1) | US20060142566A1 (en) |
EP (1) | EP1551808A1 (en) |
JP (1) | JP2006504710A (en) |
KR (1) | KR20050071549A (en) |
CN (2) | CN1703404A (en) |
AR (1) | AR041544A1 (en) |
AU (1) | AU2003276055B2 (en) |
BR (1) | BR0315113A (en) |
CA (1) | CA2501237A1 (en) |
EC (1) | ECSP055738A (en) |
GB (1) | GB0223224D0 (en) |
HK (1) | HK1079790A1 (en) |
MX (1) | MXPA05003737A (en) |
NO (1) | NO20052244L (en) |
PE (1) | PE20040686A1 (en) |
PL (1) | PL376379A1 (en) |
RU (1) | RU2005114350A (en) |
TW (1) | TW200413324A (en) |
WO (1) | WO2004031155A1 (en) |
ZA (1) | ZA200502561B (en) |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004071513A1 (en) * | 2003-02-17 | 2004-08-26 | Novartis Ag | Use of r-10-hydroxy-10, 11-dihydro-carbamazepine in neuropathic pain |
WO2007012793A1 (en) * | 2005-07-29 | 2007-02-01 | Portela & C.A., S.A. | Asymmetric catalytic reduction of oxcarbazepine |
WO2007117166A1 (en) * | 2006-04-11 | 2007-10-18 | Bial - Portela & C.A., S.A. | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
JP2008088090A (en) * | 2006-09-29 | 2008-04-17 | Kanto Chem Co Inc | Manufacturing method of optically active quinuclidinols having substituent group at 2-position |
EP1935880A1 (en) | 2004-11-17 | 2008-06-25 | Portela & Ca., S.A. | Sulphonylated diphenylethylenediamines, method for their preparation and use in transfer hydrogenation catalysis |
WO2011045648A3 (en) * | 2009-10-12 | 2011-06-09 | Matrix Laboratories Limited | Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof |
WO2011131315A1 (en) | 2010-04-23 | 2011-10-27 | Archimica Gmbh | Process for the asymmetric transfer hydrogenation of ketones |
CN102250005A (en) * | 2010-05-19 | 2011-11-23 | 浙江九洲药物科技有限公司 | Preparation method of Eslicarbazepine |
WO2012120356A3 (en) * | 2011-03-08 | 2013-01-24 | Jubilant Life Sciences Limited | Process for the preparation of (s)-(+)-or (r)-(-)-10 hydroxy dihydrodibenz[b,f]azepines by enantioselective reduction of 10, 11-dihydro-10-oxo-5h-dibenz[b,f]azepines and polymorphs thereof |
WO2013167985A1 (en) * | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological disorders |
CN103483257A (en) * | 2013-09-06 | 2014-01-01 | 江苏同禾药业有限公司 | Method for synthesizing iminostilbene |
WO2014049550A1 (en) | 2012-09-26 | 2014-04-03 | Ranbaxy Laboratories Limited | Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
US9102649B1 (en) | 2014-09-29 | 2015-08-11 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9174931B2 (en) | 2013-06-04 | 2015-11-03 | Cellix Bio Private Limited | Compositions for the treatment of diabetes and pre-diabetes |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
EP3064490A1 (en) | 2015-03-06 | 2016-09-07 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9580383B2 (en) | 2012-05-23 | 2017-02-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
US9642915B2 (en) | 2012-05-07 | 2017-05-09 | Cellix Bio Private Limited | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
US9725404B2 (en) | 2014-10-27 | 2017-08-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
US9763954B2 (en) | 2007-01-15 | 2017-09-19 | Bial—Portela & Ca, S.A. | Therapeutical uses of eslicarbazepine |
US9771355B2 (en) | 2014-09-26 | 2017-09-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US10227301B2 (en) | 2015-01-06 | 2019-03-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
US10675287B2 (en) | 2005-05-06 | 2020-06-09 | Bial-Portela & Ca S.A. | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9029540B2 (en) * | 2013-07-01 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Ruthenium catalysts and their use for asymmetric reduction of ketones |
CN107033079B (en) * | 2016-10-17 | 2020-07-28 | 扬子江药业集团北京海燕药业有限公司 | Preparation method of eslicarbazepine acetate |
CN112679433A (en) * | 2019-10-18 | 2021-04-20 | 浙江九洲药业股份有限公司 | Preparation method of allicetin |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000076942A1 (en) * | 1999-06-15 | 2000-12-21 | Rhodia Chimie | Sulphonylamides and carboxamides and their use in asymmetrical catalysis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT101732B (en) * | 1995-06-30 | 1997-12-31 | Portela & Ca Sa | SUBSTITUTED AZEPINES PROCESS FOR THE PREPARATION OF THE PHARMACEUTICAL COMPOSITIONS CONTAINED THEREOF AND USES OF THE NEW COMPOUNDS IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS EMPLOYED IN DISEASES OF THE NERVOUS SYSTEM |
JP2004526706A (en) * | 2001-02-12 | 2004-09-02 | テバ ファーマシューティカル インダストリーズ リミティド | New crystalline forms of oxcarbazepine and methods for their preparation |
-
2002
- 2002-10-07 GB GBGB0223224.7A patent/GB0223224D0/en not_active Ceased
-
2003
- 2003-10-06 CN CNA2003801013117A patent/CN1703404A/en active Pending
- 2003-10-06 RU RU2005114350/04A patent/RU2005114350A/en not_active Application Discontinuation
- 2003-10-06 KR KR1020057005920A patent/KR20050071549A/en not_active Application Discontinuation
- 2003-10-06 WO PCT/EP2003/011034 patent/WO2004031155A1/en active Application Filing
- 2003-10-06 MX MXPA05003737A patent/MXPA05003737A/en not_active Application Discontinuation
- 2003-10-06 CA CA002501237A patent/CA2501237A1/en not_active Abandoned
- 2003-10-06 CN CNA2007101126346A patent/CN101062932A/en active Pending
- 2003-10-06 PL PL03376379A patent/PL376379A1/en unknown
- 2003-10-06 JP JP2004540788A patent/JP2006504710A/en active Pending
- 2003-10-06 AU AU2003276055A patent/AU2003276055B2/en not_active Expired - Fee Related
- 2003-10-06 EP EP03798930A patent/EP1551808A1/en not_active Withdrawn
- 2003-10-06 BR BR0315113-1A patent/BR0315113A/en not_active IP Right Cessation
- 2003-10-06 US US10/530,617 patent/US20060142566A1/en not_active Abandoned
- 2003-10-07 TW TW092127799A patent/TW200413324A/en unknown
- 2003-10-07 PE PE2003001022A patent/PE20040686A1/en not_active Application Discontinuation
- 2003-10-07 AR ARP030103648A patent/AR041544A1/en not_active Application Discontinuation
-
2005
- 2005-03-30 ZA ZA200502561A patent/ZA200502561B/en unknown
- 2005-04-06 EC EC2005005738A patent/ECSP055738A/en unknown
- 2005-05-06 NO NO20052244A patent/NO20052244L/en not_active Application Discontinuation
- 2005-12-30 HK HK05112208.8A patent/HK1079790A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000076942A1 (en) * | 1999-06-15 | 2000-12-21 | Rhodia Chimie | Sulphonylamides and carboxamides and their use in asymmetrical catalysis |
Non-Patent Citations (5)
Title |
---|
BENES J ET AL: "Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine-5-carboxamide Derivatives", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, 1999, pages 2582 - 2587, XP002206156, ISSN: 0022-2623 * |
HAACK K J ET AL: "The catalyst precursor, catalyst and intermediate in the RuII-promoted asymmetric hydrogen transfer between alcohols and ketones", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 36, no. 3, 1997, pages 285 - 288, XP002092423, ISSN: 0570-0833 * |
LISGARTEN, JOHN N. ET AL: "The structure of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5- carboxamide, an anticonvulsant drug molecule", ACTA CRYSTALLOGRAPHICA, SECTION C: CRYSTAL STRUCTURE COMMUNICATIONS (1989), C45(4), 656-8, XP008027747 * |
MOHAR, BARBARA ET AL: "Highly enantioselective synthesis via dynamic kinetic resolution under transfer hydrogenation using Ru(.eta.6-arene)-N- perfluorosulfonyl-1,2-diamine catalysts: a first insight into the relationship of the ligand's pKa and the catalyst activity", CHEMICAL COMMUNICATIONS (CAMBRIDGE, UNITED KINGDOM) (2001), (24), 2572-2573, XP002270702 * |
TARAN F ET AL: "HIGH-THROUGHPUT SCREENING OF ENANTIOSELECTIVE CATALYSTS BY IMMUNOASSAY", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 41, no. 1, 4 January 2002 (2002-01-04), pages 124 - 127, XP001102322, ISSN: 0570-0833 * |
Cited By (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004071513A1 (en) * | 2003-02-17 | 2004-08-26 | Novartis Ag | Use of r-10-hydroxy-10, 11-dihydro-carbamazepine in neuropathic pain |
EP1935880A1 (en) | 2004-11-17 | 2008-06-25 | Portela & Ca., S.A. | Sulphonylated diphenylethylenediamines, method for their preparation and use in transfer hydrogenation catalysis |
US8859815B2 (en) | 2004-11-17 | 2014-10-14 | Bial-Portela & C.A., S.A. | Sulphonylated diphenylethylenediamines, method for their preparation and use in transfer hydrogenation catalysis |
US7667075B2 (en) | 2004-11-17 | 2010-02-23 | Bial - Portela & Ca, S.A. | Sulphonylated diphenylethylenediamines, method for their preparation and use in transfer hydrogenation catalysis |
US11364247B2 (en) | 2005-05-06 | 2022-06-21 | Bial-Portela & Ca S.A. | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
US10675287B2 (en) | 2005-05-06 | 2020-06-09 | Bial-Portela & Ca S.A. | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
US10695354B2 (en) | 2005-05-06 | 2020-06-30 | Bial-Portela & Ca S.A. | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
US10702536B2 (en) | 2005-05-06 | 2020-07-07 | Bial-Portela & Ca S.A. | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
US9643929B2 (en) | 2005-07-29 | 2017-05-09 | Bial—Portela & Ca, S.A. | Asymmetric catalytic reduction of oxcarbazepine |
KR101362281B1 (en) | 2005-07-29 | 2014-02-12 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | Asymmetric catalytic reduction of oxcarbazepine |
WO2007012793A1 (en) * | 2005-07-29 | 2007-02-01 | Portela & C.A., S.A. | Asymmetric catalytic reduction of oxcarbazepine |
US9206135B2 (en) | 2005-07-29 | 2015-12-08 | Bial-Portela & Ca, S.A. | Asymmetric catalytic reduction of oxcarbazepine |
JP2009502893A (en) * | 2005-07-29 | 2009-01-29 | ビーアイエーエル−ポルテラ・アンド・シー.エー.、エス.エー. | Asymmetric catalytic reduction of oxcarbazepine |
US8288532B2 (en) | 2005-07-29 | 2012-10-16 | Bial-Portela & Ca., S.A. | Asymmetric catalytic reduction of oxcarbazepine |
AU2006273874B2 (en) * | 2005-07-29 | 2013-01-10 | Bial - Portela & Ca, S.A. | Asymmetric catalytic reduction of oxcarbazepine |
JP2013173764A (en) * | 2005-07-29 | 2013-09-05 | Bial-Portela & Ca Sa | Asymmetric catalytic reduction of oxcarbazepine |
CN101277937B (en) * | 2005-07-29 | 2010-12-08 | 坡特拉有限公司 | Asymmetric catalytic reduction of oxcarbazepine |
EP2319836A1 (en) | 2005-07-29 | 2011-05-11 | Bial-Portela & CA, S.A. | Asymmetric catalytic reduction of oxcarbazepine |
WO2007117166A1 (en) * | 2006-04-11 | 2007-10-18 | Bial - Portela & C.A., S.A. | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
US8367821B2 (en) | 2006-04-11 | 2013-02-05 | BIAL—Portela & C.A., S.A. | Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation |
JP2008088090A (en) * | 2006-09-29 | 2008-04-17 | Kanto Chem Co Inc | Manufacturing method of optically active quinuclidinols having substituent group at 2-position |
US9763954B2 (en) | 2007-01-15 | 2017-09-19 | Bial—Portela & Ca, S.A. | Therapeutical uses of eslicarbazepine |
WO2011045648A3 (en) * | 2009-10-12 | 2011-06-09 | Matrix Laboratories Limited | Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof |
US8975396B2 (en) | 2010-04-23 | 2015-03-10 | Euticals Gmbh | Process for the asymmetric transfer hydrogenation of ketones |
EP2383261A1 (en) | 2010-04-23 | 2011-11-02 | Archimica GmbH | Process for the asymmetric hydrogenation of ketones |
WO2011131315A1 (en) | 2010-04-23 | 2011-10-27 | Archimica Gmbh | Process for the asymmetric transfer hydrogenation of ketones |
CN102250005A (en) * | 2010-05-19 | 2011-11-23 | 浙江九洲药物科技有限公司 | Preparation method of Eslicarbazepine |
CN102250005B (en) * | 2010-05-19 | 2015-04-08 | 浙江九洲药物科技有限公司 | Preparation method of Eslicarbazepine |
WO2012120356A3 (en) * | 2011-03-08 | 2013-01-24 | Jubilant Life Sciences Limited | Process for the preparation of (s)-(+)-or (r)-(-)-10 hydroxy dihydrodibenz[b,f]azepines by enantioselective reduction of 10, 11-dihydro-10-oxo-5h-dibenz[b,f]azepines and polymorphs thereof |
US9346760B2 (en) | 2011-03-08 | 2016-05-24 | Jubilant Life Sciences Limited | Process for the preparation of (S)-(+)- or (R)-(-)-10-hydroxy dihydrodibenz[B,F]azepines by enantioselective reduction of 10,11-dihydro-10-OXO-5H-dibenz[B,F]azepines and polymorphs thereof |
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
US9738631B2 (en) | 2012-05-07 | 2017-08-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
US9642915B2 (en) | 2012-05-07 | 2017-05-09 | Cellix Bio Private Limited | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
WO2013167985A1 (en) * | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
US9580383B2 (en) | 2012-05-23 | 2017-02-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9403793B2 (en) | 2012-07-03 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
WO2014049550A1 (en) | 2012-09-26 | 2014-04-03 | Ranbaxy Laboratories Limited | Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9174931B2 (en) | 2013-06-04 | 2015-11-03 | Cellix Bio Private Limited | Compositions for the treatment of diabetes and pre-diabetes |
CN103483257A (en) * | 2013-09-06 | 2014-01-01 | 江苏同禾药业有限公司 | Method for synthesizing iminostilbene |
US9840472B2 (en) | 2013-12-07 | 2017-12-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of mucositis |
US9771355B2 (en) | 2014-09-26 | 2017-09-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
US9102649B1 (en) | 2014-09-29 | 2015-08-11 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
US9988340B2 (en) | 2014-09-29 | 2018-06-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9725404B2 (en) | 2014-10-27 | 2017-08-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
US10343994B2 (en) | 2015-01-06 | 2019-07-09 | Mahesh Kandula | Compositions and methods for the treatment of inflammation and pain |
US10227301B2 (en) | 2015-01-06 | 2019-03-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
US9845293B2 (en) | 2015-03-06 | 2017-12-19 | F.I.S.—Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of eslicarbazepine and eslicarbazepine acetate |
EP3064490A1 (en) | 2015-03-06 | 2016-09-07 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate |
WO2016142164A1 (en) | 2015-03-06 | 2016-09-15 | F.I.S. - Fabbrica Italiana Sintetici S.P.A. | Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate |
Also Published As
Publication number | Publication date |
---|---|
TW200413324A (en) | 2004-08-01 |
GB0223224D0 (en) | 2002-11-13 |
MXPA05003737A (en) | 2005-06-17 |
RU2005114350A (en) | 2006-01-20 |
AR041544A1 (en) | 2005-05-18 |
AU2003276055A1 (en) | 2004-04-23 |
ZA200502561B (en) | 2006-02-22 |
CN1703404A (en) | 2005-11-30 |
CA2501237A1 (en) | 2004-04-15 |
CN101062932A (en) | 2007-10-31 |
BR0315113A (en) | 2005-08-23 |
NO20052244D0 (en) | 2005-05-06 |
PL376379A1 (en) | 2005-12-27 |
ECSP055738A (en) | 2005-07-06 |
KR20050071549A (en) | 2005-07-07 |
JP2006504710A (en) | 2006-02-09 |
EP1551808A1 (en) | 2005-07-13 |
PE20040686A1 (en) | 2004-10-29 |
NO20052244L (en) | 2005-07-07 |
US20060142566A1 (en) | 2006-06-29 |
AU2003276055B2 (en) | 2008-01-03 |
HK1079790A1 (en) | 2006-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003276055B2 (en) | Enantioselective process for the preparation of both enantiomers of 10,11-dihydro-10-hydroxy-5H-dibenz [b,f]azepine-5-carboxamide and new crystal forms thereof | |
ES2569483T3 (en) | Methods to synthesize cinacalcet and salts thereof | |
CN105518005B (en) | Tricyclic pyridine-carboxamides derivatives as ROCK inhibitor | |
EP3283170A1 (en) | An antimicrobial compound | |
US20040106800A1 (en) | 4,5-Dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity | |
JP2004518763A (en) | 4,5-Dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
CN109608442B (en) | Pyrimidine derivative, preparation method and application thereof | |
CN101142197A (en) | N-hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations | |
CN103889981A (en) | Tricyclic compounds as anticancer agents | |
EP1268466A1 (en) | Decahydro-isoquinolines | |
KR20130046436A (en) | Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same | |
Oliva-Madrid et al. | Insertion reactions on carbopalladated benzyne: from eight-to nine-and ten-membered palladacycles. Applications to the synthesis of N-heterocycles | |
WO2021001288A9 (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
PL95166B1 (en) | ||
WO2001072710A1 (en) | Heterocycle derivatives and drugs | |
JPH10504820A (en) | Use of N-substituted phenothiazines | |
KR20200036755A (en) | Novel Process For The Preparation Of (-)-Cibenzoline Succinate | |
CN114773348A (en) | Preparation method and intermediate of midazolam | |
KR100616099B1 (en) | Piperazinylalkyl isooxazole derivatives having selective antagonism of T-type calcium channel | |
Čudić et al. | Synthesis of cyclo-bis-intercaland receptor molecules with phenanthridinium units | |
JP4530853B2 (en) | Anthranilic acid derivative having anti-cholecystokinin activity (anti-CCK-1), process for producing the same and pharmaceutical use | |
KR20080010168A (en) | Precursors of supramolecular capsule for ammonium ions, supramolecular capsule for ammonium ions, self-assembly method and disassembly method for the same | |
JP2009537614A (en) | 2-alkoxy-3,4,5-trihydroxy-alkylamido-benzazepine, its preparation and use thereof and compositions containing it | |
CN101238111A (en) | Cyclic ketal beta-secretase inhibitors for the treatment of Alzheimer's disease | |
NL8603236A (en) | OPTICALLY ACTIVE 2-CHLORO-12- (3-DIMETHYLAMINO-2-METHYL-PROPYL) -12H DIZODANE, G1,3,6DIOXAZOCINES AND A METHOD FOR THE PREPARATION THEREOF. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SY TJ TM TN TR TT UA US UZ VC VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005/02561 Country of ref document: ZA Ref document number: 200502561 Country of ref document: ZA Ref document number: 2003276055 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 167796 Country of ref document: IL Ref document number: 2003798930 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2501237 Country of ref document: CA Ref document number: 539201 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 552/CHENP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057005920 Country of ref document: KR Ref document number: 2004540788 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/003737 Country of ref document: MX Ref document number: 376379 Country of ref document: PL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 05033830 Country of ref document: CO Ref document number: 20038A13117 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200500610 Country of ref document: VN |
|
ENP | Entry into the national phase |
Ref document number: 2005114350 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-500655 Country of ref document: PH |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057005920 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003798930 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006142566 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10530617 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10530617 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2003276055 Country of ref document: AU Date of ref document: 20031006 Kind code of ref document: B |